XTL Net Debt vs Accounts Payable Analysis
| XTLB Stock | USD 2.10 0.22 11.70% |
XTL Biopharmaceutica financial indicator trend analysis is more than just analyzing XTL Biopharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether XTL Biopharmaceuticals is a good investment. Please check the relationship between XTL Biopharmaceutica Net Debt and its Accounts Payable accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Net Debt vs Accounts Payable
Net Debt vs Accounts Payable Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of XTL Biopharmaceuticals Net Debt account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between XTL Biopharmaceutica's Net Debt and Accounts Payable is -0.22. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of XTL Biopharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of XTL Biopharmaceutica's Net Debt and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of XTL Biopharmaceuticals Ltd are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Debt i.e., XTL Biopharmaceutica's Net Debt and Accounts Payable go up and down completely randomly.
Correlation Coefficient | -0.22 |
| Relationship Direction | Negative |
| Relationship Strength | Insignificant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Accounts Payable
An accounting item on the balance sheet that represents XTL Biopharmaceutica obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of XTL Biopharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Most indicators from XTL Biopharmaceutica's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into XTL Biopharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, XTL Biopharmaceutica's Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 3.9 M, whereas Selling General Administrative is forecasted to decline to about 697.3 K.
XTL Biopharmaceutica fundamental ratios Correlations
Click cells to compare fundamentals
XTL Biopharmaceutica Account Relationship Matchups
High Positive Relationship
High Negative Relationship
XTL Biopharmaceutica fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 7.2M | 6.5M | 6.6M | 4.2M | 2.4M | 2.3M | |
| Total Stockholder Equity | 7.0M | 6.2M | 5.3M | 4.0M | 2.2M | 2.1M | |
| Common Stock Shares Outstanding | 5.1M | 514.2M | 615.5M | 544.9M | 544.9M | 572.2M | |
| Liabilities And Stockholders Equity | 7.2M | 6.5M | 6.6M | 4.2M | 2.4M | 2.3M | |
| Total Liab | 232K | 254K | 1.3M | 187K | 206K | 195.7K | |
| Other Current Liab | 231K | 252K | 229K | 185K | 205K | 194.8K | |
| Total Current Liabilities | 232K | 254K | 231K | 187K | 206K | 195.7K | |
| Other Liab | 1.0M | 465K | 2.6M | 1.1M | 1.2M | 1.3M | |
| Net Debt | (4.5M) | (3.6M) | (3.0M) | (2.1M) | (1.4M) | (1.5M) | |
| Retained Earnings | (153.9M) | (154.7M) | (155.1M) | (156.5M) | (158.2M) | (166.2M) | |
| Cash | 4.5M | 3.6M | 3.0M | 2.1M | 1.4M | 1.3M | |
| Cash And Short Term Investments | 6.7M | 6.0M | 6.1M | 3.7M | 2.0M | 1.9M | |
| Short Term Investments | 2.3M | 2.4M | 3.2M | 1.6M | 605K | 574.8K | |
| Non Current Liabilities Total | 2.7M | 0.0 | 1K | 2.6M | 1.1M | 2K | |
| Other Current Assets | 102K | 79K | 110K | 85K | 40K | 68K | |
| Total Current Assets | 6.8M | 6.1M | 6.2M | 3.8M | 2.0M | 1.9M | |
| Net Tangible Assets | 6.6M | 3.2M | 5.0M | 3.6M | 4.2M | 4.6M | |
| Net Invested Capital | 7.0M | 6.2M | 5.3M | 4.0M | 2.2M | 4.2M | |
| Net Working Capital | 6.6M | 5.9M | 6.0M | 3.6M | 1.8M | 1.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether XTL Biopharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of XTL Biopharmaceutica's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Xtl Biopharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Xtl Biopharmaceuticals Ltd Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in XTL Biopharmaceuticals Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of XTL Biopharmaceutica. If investors know XTL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about XTL Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.76) | Earnings Share (0.03) | Return On Assets (0.14) | Return On Equity (0.13) |
The market value of XTL Biopharmaceuticals is measured differently than its book value, which is the value of XTL that is recorded on the company's balance sheet. Investors also form their own opinion of XTL Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is XTL Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because XTL Biopharmaceutica's market value can be influenced by many factors that don't directly affect XTL Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between XTL Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if XTL Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, XTL Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.